Summer Street Reiterates Buy on Vertex Pharmaceuticals (VRTX)

By admin | 6 years ago

Vertex Pharmaceuticals (NASDAQ: VRTX)‘s stock had its “buy” rating reiterated by equities research analysts at Summer Street in a research note issued to investors on Tuesday.

VRTX has been the subject of a number of other recent research reports. Analysts at Barclays Capital (NYSE: BCS) raised their price target on shares of Vertex Pharmaceuticals from $44.00 to $77.00 in a research note to investors on Tuesday. They now have an “overweight” rating on the stock. Separately, analysts at Wells Fargo & Co. (NYSE: WFC) upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday. Finally, analysts at Morgan Stanley (NYSE: MS) upgraded shares of Vertex Pharmaceuticals from an “underweight” rating to an “equal weight” rating in a research note to investors on Tuesday. They now have a $51.00 price target on the stock.

Shares of Vertex Pharmaceuticals opened at 64.16 on Tuesday. Vertex Pharmaceuticals has a 52 week low of $26.50 and a 52 week high of $64.50. The company has a market cap of $13.529 billion and a P/E ratio of 45.63.

Vertex Pharmaceuticals last announced its earnings results on Thursday, April 26th. The company reported $0.43 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.57 by $0.14. The company’s quarterly revenue was up 496.5% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $0.72 earnings per share next quarter.

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

About the author